Landmark Long-Term Overall Survival Validation at ESMO
Clinical findings presented at the European Society for Medical Oncology (ESMO) congress in Madrid on Friday delivered a major scientific victory for targeted cancer interventions. The six-year follow-up data demonstrated that adding Novartis' CDK4/6 inhibitor Kisqali (ribociclib) to standard adjuvant endocrine therapy yielded a statistically significant 19% reduction in the risk of mortality among women with high-risk, early-stage disease.
At the six-year benchmark, 91.9% of women in the Kisqali combination cohort survived, versus 89.7% among those maintained solely on endocrine monotherapy. Crucially, the absolute overall survival advantage widened progressively from 1.2 percentage points at the five-year mark to 2.1 percentage points at six years, confirming durable, compounding protective efficacy.
The initial expectation was that it would take about 10 years of follow-up to show a survival difference; turns out we're seeing a difference even sooner.

















